A randomized phase III study of adjuvant platinum/docetaxel chemotherapy with or without radiation therapy in patients with gastric cancer (Journal article)
Bamias, A./ Karina, M./ Papakostas, P./ Kostopoulos, I./ Bobos, M./ Vourli, G./ Samantas, E./ Christodoulou, Ch/ Pentheroudakis, G./ Pectasides, D./ Dimopoulos, M. A./ Fountzilas, G.
The optimal adjuvant treatment for gastric cancer remains controversial. We compared the efficacy of a docetaxel and platinum adjuvant chemotherapy regimen, in patients with high-risk gastric cancer, with that of the same chemotherapy plus radiation therapy (RT). In addition, we evaluated the prognostic and/or predictive value of a panel of molecular markers. Patients with histologically proven, radically resected gastric cancer, stage > or =T3 and/or N+ were randomized to 6 cycles of docetaxel with cisplatin, both at 75 mg/m2 every 3 weeks (arm A) or the same treatment with RT (arm B; 45 Gy). Due to excessive nausea and vomiting, cisplatin was substituted by carboplatin at AUC (area under the curve) of 5 after the first 45 patients (22 group A, 23 group B). The prognostic value of EGFR, ERCC1, HER2, MET/HGFR, MAP-Tau, and PTEN expression was also studied in a subset of 67 patients using immunohistochemistry on tissue microarrays (TMAs). A total of 147 patients were randomized. After a median follow-up of 53.7 months, no differences in overall (OS) and disease-free survival (DFS) were found between the two arms. The most common grade 3/4 toxicities for arms A and B (excluding alopecia) were non-febrile neutropenia (11 and 17%, respectively), febrile neutropenia (9 and 7%) and diarrhea (7 and 4%, respectively). Patients with ERCC1 positive tumors had significantly longer median DFS (33.1 vs. 11.8 months, Wald P = 0.016) and OS (63.2 vs. 18.8 months, Wald P = 0.046). Our results indicate that the addition of RT to platinum/docetaxel adjuvant chemotherapy does not appear to improve survival in high-risk, radically resected gastric cancer. However, the possibility that a benefit by the addition of RT was not detected due to decreased power of the study should not be excluded.
|Institution and School/Department of submitter:||Πανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικής|
|Keywords:||Adult,Aged,Antineoplastic Combined Chemotherapy Protocols/adverse effects/*therapeutic use,Carboplatin/administration & dosage/adverse effects,Chemotherapy, Adjuvant,Cisplatin/administration & dosage/adverse effects,Combined Modality Therapy,Diarrhea/chemically induced,Female,Humans,Immunohistochemistry,Kaplan-Meier Estimate,Male,Middle Aged,Neutropenia/chemically induced,Prognosis,Receptor, Epidermal Growth Factor/analysis,Receptor, erbB-2/analysis,Stomach Neoplasms/*drug therapy/metabolism/pathology/*radiotherapy,Taxoids/administration & dosage/adverse effects,Tissue Array Analysis,Treatment Outcome,Tumor Markers, Biological/analysis|
|Appears in Collections:||Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά)|
Files in This Item:
|Bamias-2010-A randomized phase I.pdf||640 kB||Adobe PDF||View/Open Request a copy|
Please use this identifier to cite or link to this item:This item is a favorite for 0 people.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.